false Q3 0001478320 --12-31 false true false false true true true true true true P4Y us-gaap:AccountingStandardsUpdate201602Member P9Y7M28D P5Y3M7D P5Y3M7D 0.705 0.643 17.68 7.80 48.54 47.81 P6Y29D P6Y29D 0.004 0.014 0.017 0.025 0.730 0.729 0001478320 2020-01-01 2020-09-30 xbrli:shares 0001478320 2020-10-31 iso4217:USD 0001478320 2020-09-30 0001478320 2019-12-31 iso4217:USD xbrli:shares 0001478320 adpt:SequencingRevenueMember 2020-07-01 2020-09-30 0001478320 adpt:SequencingRevenueMember 2019-07-01 2019-09-30 0001478320 adpt:SequencingRevenueMember 2020-01-01 2020-09-30 0001478320 adpt:SequencingRevenueMember 2019-01-01 2019-09-30 0001478320 adpt:DevelopmentRevenueMember 2020-07-01 2020-09-30 0001478320 adpt:DevelopmentRevenueMember 2019-07-01 2019-09-30 0001478320 adpt:DevelopmentRevenueMember 2020-01-01 2020-09-30 0001478320 adpt:DevelopmentRevenueMember 2019-01-01 2019-09-30 0001478320 2020-07-01 2020-09-30 0001478320 2019-07-01 2019-09-30 0001478320 2019-01-01 2019-09-30 0001478320 us-gaap:ConvertiblePreferredStockMember 2019-06-30 0001478320 us-gaap:CommonStockMember 2019-06-30 0001478320 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001478320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0001478320 us-gaap:RetainedEarningsMember 2019-06-30 0001478320 2019-06-30 0001478320 us-gaap:CommonStockMember 2019-07-01 2019-09-30 0001478320 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0001478320 us-gaap:ConvertiblePreferredStockMember 2019-07-01 2019-09-30 0001478320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-07-01 2019-09-30 0001478320 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0001478320 us-gaap:CommonStockMember 2019-09-30 0001478320 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0001478320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-30 0001478320 us-gaap:RetainedEarningsMember 2019-09-30 0001478320 2019-09-30 0001478320 us-gaap:CommonStockMember 2020-06-30 0001478320 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001478320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0001478320 us-gaap:RetainedEarningsMember 2020-06-30 0001478320 2020-06-30 0001478320 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0001478320 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0001478320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-07-01 2020-09-30 0001478320 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0001478320 us-gaap:CommonStockMember 2020-09-30 0001478320 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001478320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-09-30 0001478320 us-gaap:RetainedEarningsMember 2020-09-30 0001478320 us-gaap:ConvertiblePreferredStockMember 2018-12-31 0001478320 us-gaap:CommonStockMember 2018-12-31 0001478320 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001478320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001478320 us-gaap:RetainedEarningsMember 2018-12-31 0001478320 2018-12-31 0001478320 us-gaap:CommonStockMember 2019-01-01 2019-09-30 0001478320 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-09-30 0001478320 us-gaap:ConvertiblePreferredStockMember 2019-01-01 2019-09-30 0001478320 us-gaap:RetainedEarningsMember 2019-01-01 2019-09-30 0001478320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-09-30 0001478320 us-gaap:CommonStockMember 2019-12-31 0001478320 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001478320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001478320 us-gaap:RetainedEarningsMember 2019-12-31 0001478320 us-gaap:CommonStockMember 2020-01-01 2020-09-30 0001478320 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-09-30 0001478320 us-gaap:RetainedEarningsMember srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2019-12-31 0001478320 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2019-12-31 0001478320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-09-30 0001478320 us-gaap:RetainedEarningsMember 2020-01-01 2020-09-30 0001478320 us-gaap:IPOMember 2019-07-01 2019-07-01 0001478320 us-gaap:IPOMember 2019-07-01 0001478320 us-gaap:OverAllotmentOptionMember 2020-07-01 2020-07-31 0001478320 us-gaap:OverAllotmentOptionMember 2020-07-31 xbrli:pure 0001478320 adpt:CustomerAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-07-01 2019-09-30 0001478320 adpt:CustomerAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-09-30 0001478320 adpt:CustomerAMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-09-30 0001478320 adpt:CustomerAMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0001478320 adpt:CustomerBMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-07-01 2019-09-30 0001478320 adpt:CustomerCMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-07-01 2020-09-30 0001478320 adpt:CustomerCMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-09-30 0001478320 adpt:GenentechIncMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-07-01 2020-09-30 0001478320 adpt:GenentechIncMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-07-01 2019-09-30 0001478320 adpt:GenentechIncMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-09-30 0001478320 adpt:GenentechIncMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-09-30 adpt:Performance_Obligation 0001478320 us-gaap:AccountingStandardsUpdate201602Member 2020-09-30 0001478320 us-gaap:AccountingStandardsUpdate201815Member 2020-09-30 0001478320 us-gaap:AccountingStandardsUpdate201912Member 2020-09-30 0001478320 adpt:MRDDevelopmentAgreementsMember 2020-07-01 2020-09-30 0001478320 adpt:MRDDevelopmentAgreementsMember 2019-07-01 2019-09-30 0001478320 adpt:MRDDevelopmentAgreementsMember 2020-01-01 2020-09-30 0001478320 adpt:MRDDevelopmentAgreementsMember 2019-01-01 2019-09-30 0001478320 adpt:MRDDevelopmentAgreementsMember srt:MaximumMember 2020-09-30 0001478320 adpt:GenentechCollaborationAgreementMember 2019-02-01 2019-02-28 0001478320 adpt:GenentechCollaborationAgreementMember srt:MinimumMember 2020-09-30 0001478320 adpt:GenentechCollaborationAgreementMember adpt:RegulatoryMilestonesMember srt:MaximumMember 2020-09-30 0001478320 adpt:GenentechCollaborationAgreementMember adpt:DevelopmentMilestonesMember srt:MaximumMember 2020-09-30 0001478320 adpt:GenentechCollaborationAgreementMember adpt:CommercialMilestonesMember srt:MaximumMember 2020-09-30 0001478320 adpt:GenentechCollaborationAgreementMember 2020-01-01 2020-09-30 0001478320 adpt:GenentechCollaborationAgreementMember srt:MinimumMember 2020-01-01 2020-09-30 0001478320 adpt:GenentechCollaborationAgreementMember srt:MaximumMember 2020-01-01 2020-09-30 0001478320 adpt:GenentechCollaborationAgreementMember 2020-07-01 2020-09-30 0001478320 adpt:GenentechCollaborationAgreementMember 2019-07-01 2019-09-30 0001478320 adpt:GenentechCollaborationAgreementMember 2019-01-01 2019-09-30 0001478320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2020-09-30 0001478320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2020-09-30 0001478320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member 2020-09-30 0001478320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-09-30 0001478320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member 2020-09-30 0001478320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2020-09-30 0001478320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2020-09-30 0001478320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2020-09-30 0001478320 us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001478320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0001478320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2019-12-31 0001478320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0001478320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2019-12-31 0001478320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0001478320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-12-31 0001478320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0001478320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0001478320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0001478320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0001478320 us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001478320 us-gaap:USGovernmentAgenciesDebtSecuritiesMember adpt:AvailableForSaleSecuritiesDebtSecuritiesCurrentMember 2020-09-30 0001478320 us-gaap:CorporateBondSecuritiesMember adpt:AvailableForSaleSecuritiesDebtSecuritiesCurrentMember 2020-09-30 0001478320 adpt:AvailableForSaleSecuritiesDebtSecuritiesCurrentMember 2020-09-30 0001478320 us-gaap:USGovernmentAgenciesDebtSecuritiesMember adpt:AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember 2020-09-30 0001478320 adpt:AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember 2020-09-30 0001478320 us-gaap:CommercialPaperMember adpt:AvailableForSaleSecuritiesDebtSecuritiesCurrentMember 2019-12-31 0001478320 us-gaap:USGovernmentAgenciesDebtSecuritiesMember adpt:AvailableForSaleSecuritiesDebtSecuritiesCurrentMember 2019-12-31 0001478320 us-gaap:CorporateBondSecuritiesMember adpt:AvailableForSaleSecuritiesDebtSecuritiesCurrentMember 2019-12-31 0001478320 adpt:AvailableForSaleSecuritiesDebtSecuritiesCurrentMember 2019-12-31 0001478320 us-gaap:USGovernmentAgenciesDebtSecuritiesMember adpt:AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember 2019-12-31 0001478320 us-gaap:CorporateBondSecuritiesMember adpt:AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember 2019-12-31 0001478320 adpt:AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember 2019-12-31 0001478320 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2020-09-30 0001478320 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2019-12-31 0001478320 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-09-30 0001478320 us-gaap:CorporateBondSecuritiesMember 2020-09-30 0001478320 2015-12-31 0001478320 us-gaap:DevelopedTechnologyRightsMember 2020-09-30 0001478320 us-gaap:IntellectualPropertyMember 2020-09-30 0001478320 us-gaap:DevelopedTechnologyRightsMember 2019-12-31 0001478320 us-gaap:IntellectualPropertyMember 2019-12-31 0001478320 us-gaap:IntellectualPropertyMember 2020-01-01 2020-09-30 0001478320 adpt:SequencingRevenueMember 2020-09-30 0001478320 adpt:SequencingRevenueMember 2019-12-31 0001478320 adpt:DevelopmentRevenueMember 2020-09-30 0001478320 adpt:DevelopmentRevenueMember 2019-12-31 0001478320 adpt:DevelopmentRevenueMember adpt:GenentechIncMember 2020-09-30 0001478320 adpt:DevelopmentRevenueMember adpt:GenentechIncMember 2019-12-31 0001478320 adpt:GenentechIncMember 2020-10-01 2020-09-30 0001478320 adpt:GenentechIncMember 2020-10-01 srt:MinimumMember 2020-09-30 0001478320 adpt:GenentechIncMember srt:MaximumMember 2020-10-01 2020-09-30 0001478320 adpt:DeferredRevenueMember 2020-01-01 2020-09-30 utr:sqft 0001478320 srt:MinimumMember 2020-09-30 0001478320 srt:MaximumMember 2020-09-30 adpt:Lease 0001478320 2019-08-31 0001478320 us-gaap:OtherNoncurrentLiabilitiesMember 2020-09-30 0001478320 us-gaap:ConvertiblePreferredStockMember 2019-06-29 2019-06-30 0001478320 us-gaap:ConvertiblePreferredStockMember 2020-09-30 adpt:Vote 0001478320 adpt:CommonStockOptionsAndRestrictedStockUnitsGrantedMember 2020-09-30 0001478320 us-gaap:EmployeeStockOptionMember adpt:TwoThousandAndNineteenEquityIncentivePlanMember 2020-09-30 0001478320 us-gaap:EmployeeStockOptionMember us-gaap:EmployeeStockMember 2020-09-30 0001478320 us-gaap:WarrantMember 2020-09-30 0001478320 adpt:TwoThousandAndNineteenEquityIncentivePlanMember srt:MaximumMember 2020-01-01 2020-01-01 0001478320 us-gaap:EmployeeStockMember srt:MaximumMember 2020-01-01 2020-01-01 0001478320 adpt:TwoThousandAndNineteenEquityIncentivePlanMember 2020-01-01 2020-01-01 0001478320 us-gaap:EmployeeStockMember 2020-01-01 2020-01-01 0001478320 adpt:SeriesCConvertiblePreferredStockMember 2014-12-31 0001478320 adpt:SeriesCConvertiblePreferredStockMember 2014-01-01 2014-12-31 0001478320 adpt:SequentaTwoThousandAndEightStockPlanMember 2020-09-30 0001478320 adpt:TwoThousandAndNineEquityIncentivePlanMember us-gaap:EmployeeStockOptionMember srt:MaximumMember 2020-01-01 2020-09-30 0001478320 adpt:TwoThousandAndNineEquityIncentivePlanMember us-gaap:EmployeeStockOptionMember 2020-09-30 0001478320 adpt:TwoThousandAndNineteenEquityIncentivePlanMember us-gaap:EmployeeStockOptionMember srt:MaximumMember 2020-01-01 2020-09-30 0001478320 adpt:TwoThousandAndNineteenEquityIncentivePlanMember us-gaap:EmployeeStockOptionMember adpt:NonEmployeeDirectorsMember 2020-01-01 2020-09-30 0001478320 adpt:TwoThousandAndNineteenEquityIncentivePlanMember 2019-12-31 0001478320 adpt:TwoThousandAndNineteenEquityIncentivePlanMember 2020-01-01 2020-09-30 0001478320 adpt:TwoThousandAndNineteenEquityIncentivePlanMember 2020-09-30 0001478320 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:RestrictedStockUnitsRSUMember adpt:TwoThousandAndNineteenEquityIncentivePlanMember 2020-09-30 0001478320 adpt:TwoThousandAndNineteenEquityIncentivePlanMember us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-09-30 0001478320 adpt:TwoThousandAndNineteenEquityIncentivePlanMember us-gaap:RestrictedStockUnitsRSUMember 2020-09-30 0001478320 adpt:TwoThousandAndNineteenEquityIncentivePlanMember us-gaap:RestrictedStockUnitsRSUMember 2019-12-31 0001478320 srt:MinimumMember 2020-01-01 2020-09-30 0001478320 srt:MinimumMember 2019-01-01 2019-09-30 0001478320 srt:MaximumMember 2020-01-01 2020-09-30 0001478320 srt:MaximumMember 2019-01-01 2019-09-30 0001478320 us-gaap:ValuationTechniqueOptionPricingModelMember 2020-01-01 2020-09-30 0001478320 us-gaap:CostOfSalesMember 2020-07-01 2020-09-30 0001478320 us-gaap:CostOfSalesMember 2019-07-01 2019-09-30 0001478320 us-gaap:CostOfSalesMember 2020-01-01 2020-09-30 0001478320 us-gaap:CostOfSalesMember 2019-01-01 2019-09-30 0001478320 us-gaap:ResearchAndDevelopmentExpenseMember 2020-07-01 2020-09-30 0001478320 us-gaap:ResearchAndDevelopmentExpenseMember 2019-07-01 2019-09-30 0001478320 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-09-30 0001478320 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-09-30 0001478320 us-gaap:SellingAndMarketingExpenseMember 2020-07-01 2020-09-30 0001478320 us-gaap:SellingAndMarketingExpenseMember 2019-07-01 2019-09-30 0001478320 us-gaap:SellingAndMarketingExpenseMember 2020-01-01 2020-09-30 0001478320 us-gaap:SellingAndMarketingExpenseMember 2019-01-01 2019-09-30 0001478320 us-gaap:GeneralAndAdministrativeExpenseMember 2020-07-01 2020-09-30 0001478320 us-gaap:GeneralAndAdministrativeExpenseMember 2019-07-01 2019-09-30 0001478320 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-09-30 0001478320 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-09-30 0001478320 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-09-30 0001478320 us-gaap:RestrictedStockUnitsRSUMember 2020-09-30 0001478320 2019-01-01 2019-12-31 0001478320 us-gaap:EmployeeStockOptionMember 2020-07-01 2020-09-30 0001478320 us-gaap:EmployeeStockOptionMember 2019-07-01 2019-09-30 0001478320 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-09-30 0001478320 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-09-30 0001478320 adpt:UnvestedRestrictedStockUnitsMember 2020-07-01 2020-09-30 0001478320 adpt:UnvestedRestrictedStockUnitsMember 2019-07-01 2019-09-30 0001478320 adpt:UnvestedRestrictedStockUnitsMember 2020-01-01 2020-09-30 0001478320 adpt:UnvestedRestrictedStockUnitsMember 2019-01-01 2019-09-30 0001478320 adpt:CommonStockWarrantsMember 2020-07-01 2020-09-30 0001478320 adpt:CommonStockWarrantsMember 2019-07-01 2019-09-30 0001478320 adpt:CommonStockWarrantsMember 2020-01-01 2020-09-30 0001478320 adpt:CommonStockWarrantsMember 2019-01-01 2019-09-30 0001478320 adpt:ConvertiblePreferredStockWarrantsMember 2019-01-01 2019-09-30

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 10-Q

 

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2020

OR

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from _____to _____

Commission File Number: 001-38957

 

ADAPTIVE BIOTECHNOLOGIES CORPORATION

(Exact Name of Registrant as Specified in its Charter)

 

 

Washington

27-0907024

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer
Identification No.)

1551 Eastlake Avenue East, Suite 200

Seattle, Washington

98102

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (206) 659-0067

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Common stock, par value $0.0001 per share

 

ADPT

 

The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     Yes      No  

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes      No  

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

 

  

Accelerated filer

 

 

 

 

 

Non-accelerated filer

 

  

Smaller reporting company

 

 

 

 

 

 

 

 

 

 

 

 

Emerging growth company

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes      No  

As of October 31, 2020, the registrant had 136,772,417 shares of common stock, $0.0001 par value per share, outstanding.

 

 

 


Table of Contents

 

 

 

Page

PART I.

FINANCIAL INFORMATION

4

Item 1.

Financial Statements (Unaudited)

4

 

Condensed Balance Sheets

4

 

Condensed Statements of Operations

5

 

Condensed Statements of Comprehensive Loss

6

 

Condensed Statements of Convertible Preferred Stock and Shareholders’ (Deficit) Equity

7

 

Condensed Statements of Cash Flows

9

 

Notes to Unaudited Condensed Financial Statements

10

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

26

Item 3.

Quantitative and Qualitative Disclosures about Market Risk

38

Item 4.

Controls and Procedures

38

PART II.

OTHER INFORMATION

39

Item 1.

Legal Proceedings

39

Item 1A.

Risk Factors

39

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

41

Item 3.

Defaults Upon Senior Securities

41

Item 4.

Mine Safety Disclosures

42

Item 5.

Other Information

42

Item 6.

Exhibits

42

Signatures

43

 

 

 


Adaptive Biotechnologies Corporation

 

FORWARD-LOOKING STATEMENTS

This report contains forward-looking statements that are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this report other than statements of historical fact are forward-looking statements, which include but are not limited to, statements about:

 

our ability to leverage and extend our immune medicine platform to discover, develop and commercialize our products and services, including those related to COVID-19, such as our ability to develop a map of the T cell response to the SARS-CoV-2 virus (“immunoSEQ T-MAP COVID”) and the development of a T cell-based clinical diagnostic product for COVID-19 (“T-Detect COVID”), particularly in light of the novelty of immune medicine and our methods;

 

our ability to obtain regulatory clearance, authorization and approval for such products and services;

 

our collaboration with Genentech, Inc. (“Genentech”) and ability to develop and commercialize cellular therapeutics, including our ability to achieve milestones and realize the intended benefits of the collaboration;

 

our ability to develop a map of the interaction between the immune system and disease (“TCR-Antigen Map”) and yield insights from it that are commercially viable;

 

our expected reliance on collaborators for development and clinical testing of potential diagnostic and therapeutic product candidates, which may fail at any time due to a number of possible unforeseen events; and

 

the potential adverse effect on our business, operations and plans or timelines (including those plans and timelines related to expansion initiatives and clinical development) resulting from the recent COVID-19 pandemic, including potential impacts to our supply chain, such as longer lead times in inventory production and diminished availability of reagents or other materials.

The forward-looking statements in this report also include statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts and other matters regarding our business strategies, use of capital, results of operations and financial position and plans and objectives for future operations. In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under “Risk Factors,” “Management's Discussion and Analysis of Financial Condition and Results of Operations,” and elsewhere in this report and in other documents we file with the Securities and Exchange Commission (“SEC”) from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this report represent our views as of the date of this report.

We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

Unless otherwise stated or the context otherwise indicates, references to “we,” “us,” “our” and similar references refer to Adaptive Biotechnologies Corporation.

 

 

 

 

 

 

 

 

3


Adaptive Biotechnologies Corporation

 

PART I—FINANCIAL INFORMATION

Item 1. Financial Statements (Unaudited)

 

Condensed Balance Sheets

(in thousands, except share and per share amounts)

 

 

 

 

 

 

 

 

 

 

 

 

September 30, 2020

 

 

December 31, 2019

 

 

 

(unaudited)

 

 

 

 

 

Assets

 

 

 

 

 

 

 

 

Current assets

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

497,076

 

 

$

96,576

 

Short-term marketable securities (amortized cost of $336,840 and $479,791, respectively)

 

 

338,004

 

 

 

480,290

 

Accounts receivable, net

 

 

11,858

 

 

 

12,676

 

Inventory

 

 

10,736

 

 

 

9,069

 

Prepaid expenses and other current assets

 

 

19,684

 

 

 

14,079

 

Total current assets

 

 

877,358

 

 

 

612,690

 

Long-term assets

 

 

 

 

 

 

 

 

Property and equipment, net

 

 

31,156

 

 

 

60,355

 

Operating lease right-of-use assets

 

 

37,733

 

 

 

 

Long-term marketable securities (amortized cost of $16,203 and $105,263, respectively)

 

 

16,466

 

 

 

105,435

 

Restricted cash

 

 

2,138

 

 

 

2,138

 

Intangible assets, net

 

 

10,653

 

 

 

11,928

 

Goodwill

 

 

118,972

 

 

 

118,972

 

Other assets

 

 

997

 

 

 

784

 

Total assets

 

$

1,095,473

 

 

$

912,302

 

Liabilities and shareholders’ equity

 

 

 

 

 

 

 

 

Current liabilities

 

 

 

 

 

 

 

 

Accounts payable

 

$

5,412

 

 

$

4,453

 

Accrued liabilities

 

 

5,346

 

 

 

4,371

 

Accrued compensation and benefits

 

 

7,913

 

 

 

8,124

 

Current portion of deferred rent

 

 

 

 

 

371

 

Current operating lease liabilities

 

 

3,969

 

 

 

 

Current deferred revenue

 

 

78,192

 

 

 

60,994

 

Total current liabilities

 

 

100,832

 

 

 

78,313

 

Long-term liabilities

 

 

 

 

 

 

 

 

Deferred rent liability, less current portion

 

 

 

 

 

6,918

 

Operating lease liabilities, less current portion

 

 

42,366

 

 

 

 

Financing obligation

 

 

 

 

 

36,607

 

Deferred revenue, less current portion

 

 

174,853

 

 

 

219,332

 

Other long-term liabilities

 

 

2,375

 

 

 

93

 

Total liabilities

 

 

320,426

 

 

 

341,263

 

Commitments and contingencies (Note 9)

 

 

 

 

 

 

 

 

Shareholders’ equity

 

 

 

 

 

 

 

 

Preferred stock: $0.0001 par value, 10,000,000 shares authorized at September 30, 2020

   and December 31, 2019; no shares issued and outstanding at September 30, 2020 and

   December 31, 2019

 

 

 

 

 

 

Common stock: $0.0001 par value, 340,000,000 shares authorized at September 30, 2020

   and December 31, 2019; 136,392,256 and 125,238,142 shares issued and outstanding at

   September 30, 2020 and December 31, 2019, respectively

 

 

13

 

 

 

12

 

Additional paid-in capital

 

 

1,240,649

 

 

 

935,834

 

Accumulated other comprehensive gain

 

 

1,427

 

 

 

671

 

Accumulated deficit

 

 

(467,042

)

 

 

(365,478

)

Total shareholders’ equity

 

 

775,047

 

 

 

571,039

 

Total liabilities and shareholders’ equity

 

$

1,095,473

 

 

$

912,302

 

 

The accompanying notes are an integral part of these condensed financial statements.

 

4


Adaptive Biotechnologies Corporation

 

Condensed Statements of Operations

(in thousands, except share and per share amounts)

(unaudited)

 

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

2020

 

 

2019

 

 

2020

 

 

2019

 

Revenue

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Sequencing revenue

 

$

11,276

 

 

$

11,683

 

 

$

28,730

 

 

$

29,631

 

Development revenue

 

 

15,023

 

 

 

14,375

 

 

 

39,467

 

 

 

31,231

 

Total revenue

 

 

26,299

 

 

 

26,058

 

 

 

68,197

 

 

 

60,862

 

Operating expenses

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of revenue

 

 

6,053

 

 

 

5,601

 

 

 

16,308

 

 

 

16,323

 

Research and development

 

 

30,314

 

 

 

20,506

 

 

 

80,241

 

 

 

49,516

 

Sales and marketing

 

 

14,474

 

 

 

9,099

 

 

 

42,813

 

 

 

25,813

 

General and administrative

 

 

12,079

 

 

 

8,477

 

 

 

36,138

 

 

 

22,143

 

Amortization of intangible assets

 

 

428

 

 

 

428

 

 

 

1,275

 

 

 

1,270

 

Total operating expenses

 

 

63,348

 

 

 

44,111

 

 

 

176,775

 

 

 

115,065

 

Loss from operations

 

 

(37,049

)

 

 

(18,053

)

 

 

(108,578

)

 

 

(54,203

)

Interest and other income, net

 

 

1,018

 

 

 

4,103

 

 

 

5,805

 

 

 

6,208

 

Income tax (expense) benefit

 

 

(688

)

 

 

 

 

 

1,116

 

 

 

 

Net loss

 

 

(36,719

)

 

 

(13,950

)

 

 

(101,657

)

 

 

(47,995

)

Fair value adjustment to Series E-1 convertible preferred

   stock options

 

 

 

 

 

 

 

 

 

 

 

(964

)

Net loss attributable to common shareholders

 

$

(36,719

)

 

$

(13,950

)

 

$

(101,657

)

 

$

(48,959

)

Net loss per share attributable to common shareholders, basic

   and diluted

 

$

(0.27

)

 

$

(0.11

)

 

$

(0.79

)

 

$

(0.97

)

Weighted-average shares used in computing net loss per

   share attributable to common shareholders, basic and

   diluted

 

 

134,372,026

 

 

 

124,285,686

 

 

 

129,289,948

 

 

 

50,552,389

 

 

The accompanying notes are an integral part of these condensed financial statements.

 

5


Adaptive Biotechnologies Corporation

 

 

Condensed Statements of Comprehensive Loss

(in thousands)

(unaudited)

 

 

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

2020

 

 

2019

 

 

2020

 

 

2019

 

Net loss

 

$

(36,719

)

 

$

(13,950

)

 

$

(101,657

)

 

$

(47,995

)

Change in unrealized (loss) gain on investments

 

 

(726

)

 

 

190

 

 

 

756

 

 

 

679

 

Comprehensive loss

 

$

(37,445

)

 

$

(13,760

)

 

$

(100,901

)

 

$

(47,316

)

 

The accompanying notes are an integral part of these condensed financial statements.

 

6


Adaptive Biotechnologies Corporation

 

Condensed Statements of Convertible Preferred Stock and Shareholders’ (Deficit) Equity

(in thousands, except share amounts)

(unaudited)

 

 

 

Convertible Preferred Stock

 

 

 

Common Stock

 

 

Additional

Paid-In

 

 

Accumulated

Other

Comprehensive

 

 

Accumulated

 

 

Total

Shareholders’

(Deficit)

 

 

 

Shares

 

 

Amount

 

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Gain

 

 

Deficit

 

 

Equity

 

Balance at June 30, 2019

 

 

93,039,737

 

 

$

561,931

 

 

 

 

13,725,381

 

 

$

1

 

 

$

46,160

 

 

$

382

 

 

$

(330,917

)

 

$

(284,374

)

Proceeds from initial public offering, net of

   underwriters' discounts and commissions

 

 

 

 

 

 

 

 

 

17,250,000

 

 

 

2

 

 

 

320,848

 

 

 

 

 

 

 

 

 

320,850

 

Initial public offering costs

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(4,986

)

 

 

 

 

 

 

 

 

(4,986

)

Conversion of convertible preferred stock to common

   stock

 

 

(93,039,737

)

 

 

(561,931

)

 

 

 

93,039,737

 

 

 

9

 

 

 

561,922

 

 

 

 

 

 

 

 

 

561,931

 

Conversion of convertible preferred stock warrant to

   common stock warrant

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2,602

 

 

 

 

 

 

 

 

 

2,602

 

Issuance of common stock upon exercise of common

   stock warrants

 

 

 

 

 

 

 

 

 

54,792

 

 

 

 

 

 

9

 

 

 

 

 

 

 

 

 

9

 

Issuance of common stock for cash upon exercise of

   stock options

 

 

 

 

 

 

 

 

 

246,170

 

 

 

 

 

 

318

 

 

 

 

 

 

 

 

 

318

 

Common stock option and restricted stock unit share-

   based compensation

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

3,335

 

 

 

 

 

 

 

 

 

3,335

 

Other comprehensive income

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

190

 

 

 

 

 

 

190

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(13,950

)

 

 

(13,950

)

Balance at September 30, 2019

 

 

 

 

$

 

 

 

 

124,316,080

 

 

$

12

 

 

$

930,208

 

 

$

572

 

 

$

(344,867

)

 

$

585,925

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance at June 30, 2020

 

 

 

 

$

 

 

 

 

128,233,842

 

 

$

12

 

 

$

958,097

 

 

$

2,153

 

 

$

(430,323

)

 

$

529,939

 

Issuance of common stock upon public offering, after

   deducting underwriters' discounts and net offering

   costs payable by us

 

 

 

 

 

 

 

 

 

7,200,000

 

 

 

1

 

 

 

271,838

 

 

 

 

 

 

 

 

 

271,839

 

Issuance of common stock for cash upon exercise of

   stock options

 

 

 

 

 

 

 

 

 

958,414

 

 

 

 

 

 

4,244

 

 

 

 

 

 

 

 

 

4,244

 

Common stock option and restricted stock unit share-

   based compensation

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

6,470

 

 

 

 

 

 

 

 

 

6,470

 

Other comprehensive loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(726

)

 

 

 

 

 

(726

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(36,719

)

 

 

(36,719

)

Balance at September 30, 2020

 

 

 

 

$

 

 

 

 

136,392,256

 

 

$

13

 

 

$

1,240,649

 

 

$

1,427

 

 

$

(467,042

)

 

$

775,047

 

 

The accompanying notes are an integral part of these condensed financial statements.

7


Adaptive Biotechnologies Corporation

 

Condensed Statements of Convertible Preferred Stock and Shareholders’ (Deficit) Equity (Continued)

(in thousands, except share amounts)

(unaudited)

 

 

 

Convertible Preferred Stock

 

 

 

Common Stock

 

 

Additional

Paid-In

 

 

Accumulated

Other

Comprehensive

 

 

Accumulated

 

 

Total

Shareholders’

(Deficit)

 

 

 

Shares

 

 

Amount

 

 

 

Shares

 

 

Amount

 

 

Capital

 

 

(Loss) Gain

 

 

Deficit

 

 

Equity

 

Balance at December 31, 2018

 

 

92,790,094

 

 

$

560,858

 

 

 

 

12,841,536

 

 

$

1

 

 

$

37,902

 

 

$

(107

)

 

$

(295,908

)

 

$

(258,112

)

Proceeds from initial public offering, net of underwriters'

   discounts and commissions

 

 

 

 

 

 

 

 

 

17,250,000

 

 

 

2

 

 

 

320,848

 

 

 

 

 

 

 

 

 

320,850

 

Initial public offering costs

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(4,986

)

 

 

 

 

 

 

 

 

(4,986

)

Conversion of convertible preferred stock to common stock

 

 

(93,039,737

)

 

 

(561,931

)

 

 

 

93,039,737

 

 

 

9

 

 

 

561,922

 

 

 

 

 

 

 

 

 

561,931

 

Conversion of convertible preferred stock warrant to common

   stock warrant

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2,602

 

 

 

 

 

 

 

 

 

2,602

 

Issuance of common stock upon exercise of common stock

   warrants

 

 

 

 

 

 

 

 

 

54,792

 

 

 

 

 

 

9

 

 

 

 

 

 

 

 

 

9

 

Issuance of common stock for cash upon exercise of stock

   options

 

 

 

 

 

 

 

 

 

1,130,015

 

 

 

 

 

 

2,198

 

 

 

 

 

 

 

 

 

2,198

 

Issuance of Series E-1 convertible preferred stock for cash

   upon exercise of Series E-1 convertible preferred stock

   options at fair value

 

 

249,643

 

 

 

109

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Change in redemption value for vested Series E-1

   convertible preferred stock options

 

 

 

 

 

964

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(964

)

 

 

(964

)

Common stock option and restricted stock unit share-based

   compensation